MA47793A - Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque - Google Patents
Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïqueInfo
- Publication number
- MA47793A MA47793A MA047793A MA47793A MA47793A MA 47793 A MA47793 A MA 47793A MA 047793 A MA047793 A MA 047793A MA 47793 A MA47793 A MA 47793A MA 47793 A MA47793 A MA 47793A
- Authority
- MA
- Morocco
- Prior art keywords
- methyl
- ylethynyl
- hydrazide
- quinoline
- benzoyl
- Prior art date
Links
- 239000006185 dispersion Substances 0.000 title 1
- 239000000344 soap Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721005414 | 2017-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47793A true MA47793A (fr) | 2020-01-22 |
Family
ID=63521897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047793A MA47793A (fr) | 2017-03-15 | 2018-03-15 | Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11351123B2 (fr) |
| EP (1) | EP3596050A4 (fr) |
| JP (2) | JP7234129B2 (fr) |
| CN (1) | CN110494422A (fr) |
| AU (1) | AU2018235446B2 (fr) |
| CA (1) | CA3056348A1 (fr) |
| MA (1) | MA47793A (fr) |
| WO (1) | WO2018167802A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2911040C (fr) | 2012-05-02 | 2021-11-16 | Georgetown University | Traitement d'une synucleinopathie au moyen d'inhibiteurs de la tyrosine kinase |
| CN110494422A (zh) | 2017-03-15 | 2019-11-22 | 太阳制药先进研究有限公司 | 4-甲基-3-喹啉-3-基乙炔基-苯甲酸n’-(2-氯-6-甲基-苯甲酰基)酰肼的新型无定形分散体 |
| CN120040470A (zh) | 2018-11-20 | 2025-05-27 | 乔治敦大学 | 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法 |
| US20230301982A1 (en) * | 2020-07-31 | 2023-09-28 | Sun Pharma Advanced Research Company Limited | N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of alzheimer's disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034598B1 (ru) * | 2005-12-23 | 2020-02-25 | Ариад Фармасьютикалз, Инк. | Применение бициклических гетероарильных соединений для лечения рака |
| CN103435595A (zh) * | 2006-05-08 | 2013-12-11 | 阿里亚德医药股份有限公司 | 炔类杂芳基化合物 |
| EP2089003A1 (fr) | 2006-11-09 | 2009-08-19 | Abbott GmbH & Co. KG | Forme de dosage pharmaceutique pour l'administration orale d'un inhibiteur de la tyrosine kinase |
| US9024021B2 (en) | 2011-01-21 | 2015-05-05 | Sun Pharma Advanced Research Company Ltd. | Diarylacetylene hydrazide containing tyrosine kinase inhibitors |
| EP2802314B1 (fr) | 2012-01-13 | 2020-11-25 | XSpray Microparticles AB | Procédé de production de nanoparticules hybrides amorphes stables comprenant au moins un inhibiteur de la protéine kinase et au moins un constituant polymère stabilisant et matriciel |
| CN105744847A (zh) * | 2013-11-15 | 2016-07-06 | 帝斯曼知识产权资产管理有限公司 | 通过热熔挤出获得的略溶化合物的制剂 |
| EP2913048A1 (fr) | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Composition pharmaceutique comprenant de la trametinib |
| PT107846B (pt) * | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
| TWI803187B (zh) | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含4環性化合物的非晶質體之固體分散體及製劑 |
| WO2016090240A1 (fr) * | 2014-12-04 | 2016-06-09 | Astex Pharmaceuticals, Inc. | Compositions pharmaceutiques pour augmenter la biodisponibilité de médicaments faiblement solubles |
| CN110494422A (zh) | 2017-03-15 | 2019-11-22 | 太阳制药先进研究有限公司 | 4-甲基-3-喹啉-3-基乙炔基-苯甲酸n’-(2-氯-6-甲基-苯甲酰基)酰肼的新型无定形分散体 |
-
2018
- 2018-03-15 CN CN201880018595.XA patent/CN110494422A/zh active Pending
- 2018-03-15 MA MA047793A patent/MA47793A/fr unknown
- 2018-03-15 CA CA3056348A patent/CA3056348A1/fr active Pending
- 2018-03-15 EP EP18767879.2A patent/EP3596050A4/fr active Pending
- 2018-03-15 WO PCT/IN2018/050146 patent/WO2018167802A1/fr not_active Ceased
- 2018-03-15 AU AU2018235446A patent/AU2018235446B2/en active Active
- 2018-03-15 US US16/494,543 patent/US11351123B2/en active Active
- 2018-03-15 JP JP2019550727A patent/JP7234129B2/ja active Active
-
2021
- 2021-05-13 US US17/319,583 patent/US12194153B2/en active Active
-
2022
- 2022-12-16 JP JP2022201433A patent/JP7514292B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018235446B2 (en) | 2022-04-07 |
| US20210267906A1 (en) | 2021-09-02 |
| US11351123B2 (en) | 2022-06-07 |
| CN110494422A (zh) | 2019-11-22 |
| RU2019132068A3 (fr) | 2021-06-22 |
| WO2018167802A9 (fr) | 2019-02-07 |
| JP2020510066A (ja) | 2020-04-02 |
| WO2018167802A1 (fr) | 2018-09-20 |
| JP7234129B2 (ja) | 2023-03-07 |
| JP2023027309A (ja) | 2023-03-01 |
| US20200085751A1 (en) | 2020-03-19 |
| EP3596050A4 (fr) | 2021-01-13 |
| US12194153B2 (en) | 2025-01-14 |
| EP3596050A1 (fr) | 2020-01-22 |
| JP7514292B2 (ja) | 2024-07-10 |
| AU2018235446A1 (en) | 2019-10-03 |
| CA3056348A1 (fr) | 2018-09-20 |
| RU2019132068A (ru) | 2021-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3897522A4 (fr) | Compositions de microcapsules | |
| EP3833739A4 (fr) | Souche d'akkermansia muciniphila | |
| PL3638666T3 (pl) | Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy amidów kwasu tetrahydro- i dihydrofuranokarboksylowego | |
| EP3431075A4 (fr) | Forme galénique d'édaravone | |
| MX2018007022A (es) | Metodos para tratar la enfermedad de huntington. | |
| EP3478249A4 (fr) | Compositions de microcapsules stables | |
| EP3645146A4 (fr) | Synthèse d'oligosaccharides | |
| EP3600434A4 (fr) | Traitement de l'hypertension pulmonaire | |
| EP3407976A4 (fr) | Compositions et utilisations d'agents alpha-adrénergiques | |
| ECSP16093323A (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| MA42592A (fr) | Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak | |
| EP3373969A4 (fr) | Composés interagissant avec le glycane et méthodes d'utilisation | |
| MA47179A (fr) | Composition d'acide dicarboxylique mannuronique | |
| EP3522882A4 (fr) | Compositions d'acides aminés et utilisations associées | |
| EP3589623C0 (fr) | Preparation d' acide dicarboxylique de 2,5-furane | |
| MA47793A (fr) | Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque | |
| EP3699245A4 (fr) | Assortiment d'encres | |
| MX378847B (es) | Nuevos derivados de gamma-amanitina | |
| MA47494A (fr) | Nouvelles utilisations d'anticorps anti-sirpg | |
| EP3849527C0 (fr) | Formulations de composés de cyclosérine et leurs applications | |
| EP3585903C0 (fr) | Production de caroténoïdes et d'apocaroténoïdes | |
| CL2019002729A1 (es) | Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico. | |
| EP3297674A4 (fr) | Compositions de composé actif et benzamide et leurs méthodes d'utilisation | |
| EP3302488A4 (fr) | Nouvelle utilisation de dérivés aryl-quinoléine comme inhibiteurs de l'imitation de facteurs vasculogènes | |
| EP4003323A4 (fr) | Formulations stabilisées de dérivés de l'acide butanoïque du type 4-amino-3-substitués |